Literature DB >> 1317040

Evidence for separate neuronal mechanisms for the discriminative stimulus and catalepsy induced by delta 9-THC in the rat.

W R Prescott1, L H Gold, B R Martin.   

Abstract

The cataleptogenic effect of delta 9-THC was compared to its discriminative stimulus effects in rats. The ED50s for the discriminative stimulus and catalepsy were 0.8 and 4.0 mg/kg, respectively, while their time courses were very similar. The ED50 of delta 9-THC for catalepsy in experimentally naive rats was not different from that in rats trained with the drug discrimination procedure, indicating that the cataleptogenic effect was not appreciably attenuated by long-term exposure to low doses of delta 9-THC. Pharmacologically, the catalepsy produced by delta 9-THC more closely resembled that of haloperidol than of morphine, since anticholinergic pretreatment eliminated the delta 9-THC-induced catalepsy while pre-treatment with naloxone had no effect. Although the cataleptogenic effect of delta 9-THC could be pharmacologically manipulated by anticholinergic pre-treatment, its discriminative stimulus effects were not changed in the same animals. These results demonstrate that distinctive mechanisms of action exist for these cannabinoid-induced behaviors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1317040     DOI: 10.1007/bf02244975

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  28 in total

1.  Modification of delta9-THC-actions by cannabinol and cannabidiol in the rat.

Authors:  M Fernandes; A Schabarek; H Coper; R Hill
Journal:  Psychopharmacologia       Date:  1974

2.  Morphine catalepsy in the rat: relation to striatal dopamine metabolism.

Authors:  K Kuschinsky; O Hornykiewicz
Journal:  Eur J Pharmacol       Date:  1972-07       Impact factor: 4.432

3.  Pharmacological potency of R- and S-3'-hydroxy-delta 9-tetrahydrocannabinol: additional structural requirement for cannabinoid activity.

Authors:  B R Martin; M J Kallman; G F Kaempf; L S Harris; W L Dewey; R K Razdan
Journal:  Pharmacol Biochem Behav       Date:  1984-07       Impact factor: 3.533

4.  Possible involvement of prostaglandins in cataleptic behavior in rats.

Authors:  N Ono; R Saito; T Abiru; H Kamiya; T Furukawa
Journal:  Pharmacol Biochem Behav       Date:  1986-08       Impact factor: 3.533

5.  Catalepsy induced by morphine or haloperidol: effects of apomorphine and anticholinergic drugs.

Authors:  C Erzin-Waters; P Muller; P Seeman
Journal:  Can J Physiol Pharmacol       Date:  1976-08       Impact factor: 2.273

6.  Delta 9-Tetrahydrocannabinol, ethanol, and amphetamine as discriminative stimuli-generalization tests with other drugs.

Authors:  O F Bueno; E A Carlini; E Finkelfarb; J S Suzuki
Journal:  Psychopharmacologia       Date:  1976-04-15

Review 7.  Cannabinoid pharmacology.

Authors:  W L Dewey
Journal:  Pharmacol Rev       Date:  1986-06       Impact factor: 25.468

8.  Cannabinoid receptor localization in brain.

Authors:  M Herkenham; A B Lynn; M D Little; M R Johnson; L S Melvin; B R de Costa; K C Rice
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

9.  Enhancement of opioid cataleptic response by cortical frontal deafferentation or intrastriatal injection of NMDA-receptor antagonists.

Authors:  S Consolo; G Forloni; H Ladinsky; E Palazzi
Journal:  Brain Res       Date:  1988-05-24       Impact factor: 3.252

10.  Effect of metergoline, fenfluramine, and 8-OHDPAT on catalepsy induced by haloperidol or morphine.

Authors:  C L Broekkamp; S K Oosterloo; H H Berendsen; A M van Delft
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-08       Impact factor: 3.000

View more
  12 in total

1.  Involvement of mu-, delta- and kappa-opioid receptor subtypes in the discriminative-stimulus effects of delta-9-tetrahydrocannabinol (THC) in rats.

Authors:  Marcello Solinas; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2004-12-24       Impact factor: 4.530

2.  Assessing Allosteric Modulation of CB1 at the Receptor and Cellular Levels.

Authors:  Caitlin E Scott; Debra A Kendall
Journal:  Methods Enzymol       Date:  2017-07-05       Impact factor: 1.600

Review 3.  Are Alcohol Anti-relapsing and Alcohol Withdrawal Drugs Useful in Cannabinoid Users?

Authors:  Patrycja Kleczkowska; Irena Smaga; Małgorzata Filip; Magdalena Bujalska-Zadrozny
Journal:  Neurotox Res       Date:  2016-08-02       Impact factor: 3.911

4.  Enhancement of the behavioral effects of endogenous and exogenous cannabinoid agonists by phenylmethyl sulfonyl fluoride.

Authors:  R E Vann; D M Walentiny; J J Burston; K M Tobey; T F Gamage; J L Wiley
Journal:  Neuropharmacology       Date:  2011-10-31       Impact factor: 5.250

5.  Identification of a high-affinity binding site involved in the transport of endocannabinoids.

Authors:  S A Moore; G G Nomikos; A K Dickason-Chesterfield; D A Schober; J M Schaus; B-P Ying; Y-C Xu; L Phebus; R M A Simmons; D Li; S Iyengar; C C Felder
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-28       Impact factor: 11.205

6.  Cannabinoid tetrad effects of oral Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in male and female rats: sex, dose-effects and time course evaluations.

Authors:  Catherine F Moore; Elise M Weerts
Journal:  Psychopharmacology (Berl)       Date:  2021-10-15       Impact factor: 4.415

7.  Delta 9-tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism.

Authors:  A H Lichtman; B R Martin
Journal:  Psychopharmacology (Berl)       Date:  1996-07       Impact factor: 4.530

8.  Effect of cannabidiolic acid and ∆9-tetrahydrocannabinol on carrageenan-induced hyperalgesia and edema in a rodent model of inflammatory pain.

Authors:  Erin M Rock; Cheryl L Limebeer; Linda A Parker
Journal:  Psychopharmacology (Berl)       Date:  2018-09-17       Impact factor: 4.530

9.  Endocannabinoid modulation of dopaminergic motor circuits.

Authors:  Teresa Morera-Herreras; Cristina Miguelez; Asier Aristieta; José Ángel Ruiz-Ortega; Luisa Ugedo
Journal:  Front Pharmacol       Date:  2012-06-12       Impact factor: 5.810

Review 10.  Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection.

Authors:  Sandeep Vasant More; Dong-Kug Choi
Journal:  Mol Neurodegener       Date:  2015-04-08       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.